Clinical trials: Digestive Disease
Mucositis, Oral Complications
Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized pilot clinical trial studies whether acetylcysteine oral rinse will lessen saliva thickness and painful mouth sores in patients with head and neck cancer undergoing radiation therapy.
- Conditions
- Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
- Trial name
- NCT02123511
- Testing
- acetylcysteine, quality-of-life assessment, questionnaire administration
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Inflammatory Bowel Diseases, Skin Extra-intestinal Manifestations
Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.
- Trial name
- NCT03139032
- Testing
- APD334
- Where
- 3 sites in Belgium, Germany and 1 more
- Volunteers
- 1 people
- Sponsor
- Arena Pharmaceuticals
Eosinophilic Gastritis, Eosinophilic Duodenitis
A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic…
- Trial name
- ENIGMA 2 (NCT04322604)
- Testing
- lirentelimab (AK002)
- Where
- 60 sites in United States
- Volunteers
- 181 people
- Sponsor
- Allakos Inc.
Liver Metastases, Hepatocellular Carcinoma
Stereotactic Body Radiotherapy for Liver Tumors
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular…
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT01347333
- Testing
- Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Mercy Research
Chronic Hepatitis C
Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial
Data have suggested that consensus interferon (CIFN) has greater antiviral activity in vitro compared with interferon alfa-2a or alfa-2b.
- Trial name
- NCT00211692
- Testing
- consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin
- Volunteers
- 64 people
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered…
- Trial name
- NCT02508532
- Testing
- Avapritinib
- Where
- 19 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Blueprint Medicines Corporation
Hepatocellular Carinoma
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in…
- Trial name
- FLASH (NCT01636284)
- Testing
- JX-594 recombinant vaccina GM-CSF
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- Jennerex Biotherapeutics
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).
The effects of treatment with different doses of PEGASYS in combination with different doses of ribavirin will be evaluated in patients with CHC genotype 1 who have a high viral titer, body weight greater than 85kg (187lbs) and…
- Trial name
- NCT00077649
- Testing
- ribavirin [Copegus], peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]
- Where
- 25 sites in United States, Puerto Rico
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer
This is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active non inferiority controlled clinical trial with a 2:1 allocation.
- Trial name
- NCT03288987
- Testing
- Bevacizumab + FOLFIRI-3
- Where
- 22 sites in Iran
- Volunteers
- 126 people
- Sponsor
- AryoGen Pharmed Co.
Carcinoma, Hepatocellular
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
This is an open-label, integrated, Phase 1b/2 trial to determine the recommended Phase 2 dose (RP2D) and to evaluate the efficacy, safety, and pharmacokinetic of MSC2156119J as first-line treatment versus sorafenib in subjects…
- Trial name
- NCT01988493
- Testing
- Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg
- Where
- 43 sites in China, South Korea and 1 more
- Volunteers
- 117 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastroesophageal Reflux Disease
Clinical Studies on Bile Acids in Barrett's Esophagus
This study has two major goals: 1. To determine the effects of bile salts on causing DNA injury and activating signaling pathways that promote growth in cells from the esophagus of patients who have gastroesophageal reflux…
- Trial name
- NCT00858858
- Testing
- Ursodeoxycholic Acid
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- US Department of Veterans Affairs
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Cirrhosis, Hepatic Encephalopathy
VE303 for Treatment of Hepatic Encephalopathy (HE)
This research is studying the use of a new drug to learn about its safety and efficacy as a treatment for hepatic encephalopathy.
- Trial name
- NCT04899115
- Testing
- VE303, oral vancomycin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Patricia Bloom
Wilson Disease
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
This was a 24-month study to assess copper parameters in participants with Wilson disease (WD) treated with standard of care (SoC) medications.
- Trial name
- NCT02763215
- Testing
- Standard of Care Medications
- Where
- 10 sites in United States, Austria and 3 more
- Volunteers
- 64 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ulcerative Colitis
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting
This study evaluated the quality of life (QOL) and economic impact of adalimumab treatment in participants with ulcerative colitis (UC).
- Trial name
- InspirAda (NCT01550965)
- Testing
- Adalimumab
- Volunteers
- 463 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Esophageal Carcinoma
Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma
Surgery has been the standard of care for esophageal cancer for many years, with limited success. At present, several studies are underway nationwide which utilize chemotherapy combined with radiation therapy prior to the usual…
- Trial name
- NCT00176800
- Testing
- Tetrathiomolybdate (TM), Radiation, Surgery
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Michigan Rogel Cancer Center
Colitis, Ulcerative
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis
The purpose of the study is to evaluate the efficacy and safety of LYC-30937-EC given orally once daily in subjects with active ulcerative colitis (UC) defined as a total Mayo score (TMS) of 4-11 inclusive, with an endoscopic…
- Trial name
- NCT02762500
- Testing
- LYC-30937-EC
- Where
- 71 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Lycera Corp.
Hepatitis C
A Multiple Dose Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Participants (MK-5172-010)
The goal of this study was to compare hepatic pharmacokinetics (PK) derived from liver tissue to plasma PK after administration of grazoprevir (MK-5172) to participants with chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01537900
- Testing
- Grazoprevir
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Barrett Syndrome, Barrett's Syndrome
CLE for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia
This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).
- Conditions
- Barrett Syndrome, Barrett's Syndrome, Barrett's Esophagus, Barrett Esophagus
- Trial name
- CLEAN-MARGIN (NCT01032044)
- Testing
- Standard endoscopic evaluation, pCLE guided evaluation
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 164 people
- Sponsor
- Mauna Kea Technologies
Hepatitis C
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
The purpose of this study is to follow-up with participants from feeder studies who achieved sustained virologic response (SVR) over 24 hours posttreatment (SVR24), to assess durability of SVR, and to assess the changes in liver…
- Trial name
- NCT02753699
- Testing
- Alisporivir
- Where
- 119 sites in United States, Argentina and 20 more
- Volunteers
- 723 people
- Sponsor
- Debiopharm International SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.